<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462009000600009</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Síndrome de hiperinmunoglobulinemia E: Reporte de dos casos]]></article-title>
<article-title xml:lang="en"><![CDATA[Hyperimmunoglobulin E syndrome: report of two cases]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Puebla-Miranda]]></surname>
<given-names><![CDATA[Miriam]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Luna]]></surname>
<given-names><![CDATA[Eduwiges]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vega-Memije]]></surname>
<given-names><![CDATA[María Elisa]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Secretaría de Salud Hospital General Dr. Manuel Gea González Departamento de Dermatología]]></institution>
<addr-line><![CDATA[México D. F.]]></addr-line>
<country>México</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Secretaría de Salud Hospital General Dr. Manuel Gea González Servicio de Dermatopatología]]></institution>
<addr-line><![CDATA[México D. F.]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2009</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2009</year>
</pub-date>
<volume>66</volume>
<numero>6</numero>
<fpage>545</fpage>
<lpage>552</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462009000600009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462009000600009&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462009000600009&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Introducción. El síndrome de hiperinmunoglobulinemia E es una inmunodeficiencia sistémica poco frecuente, caracterizada por dermatitis eccematosa, abscesos fríos recurrentes, infecciones pulmonares con formación de neumatoceles, facies tosca, niveles elevados de inmunoglobulina E (IgE) en suero y eosinofilia. Casos clínicos. Caso 1. Femenino de 11 años de edad con antecedentes de neumonía recurrente, gastroenteritis de repetición, dermatitis eccematosa de predominio en pliegues, y abscesos fríos; en estudios de laboratorio destacó el hallazgo de 16 070 eosinófilos e IgE de 4 864 Ul. Manejada con gammaglobulina se observó buena respuesta clínica. Caso 2. Femenino de 12 años de edad con historia de otitis recurrente y conjuntivitis supurativa, presentaba eccema crónico generalizado e impetiginizado. En estudios de laboratorio se reportó IgE de 3 000 UI; fue manejada con dapsona, trimetropim/sulfametoxazol y metotrexate. Conclusión. Los 2 casos aquí informados presentaron piel eccematosa, infecciones recurrentes e incremento de los niveles de IgE, compatibles con síndrome de hiperinmunoglobulinemia E en la forma autosómica recesiva.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Background. Hyperimmunoglobulin E syndrome is a rare systemic immunodeficiency characterized by eczematous dermatitis, recurrent cold abscesses, lung infections with pneumatoceles, coarse facial appearance, high IgE levels and eosinophilia. Case reports. Case 1: We report the case of an 11-year-old female with a history of recurrent lung infections, recurrent gastroenteritis, eczematous dermatitis affecting the skin folds and cold abscesses. Laboratory studies showed elevated eosinophils (16 070) and IgE 4864 IU. The patient received treatment with g-globulin, showing adequate clinic response to treatment. Case 2: We present the case of a 12-year-old female with a history of recurrent otitis and suppurative conjunctivitis, showing widespread and chronic infected eczema. Laboratory studies showed elevated IgE (3 000 IU). She was treated with dapsone, trimethoprim/sulfamethoxazole and methotrexate. Conclusions. We presented two patients with eczematous skin, recurrent infections and increased IgE levels, which are compatible with hyperimmunoglobulin E autosomal recessive syndrome.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Síndrome de hiperinmunoglobulinemia E]]></kwd>
<kwd lng="es"><![CDATA[síndrome de Job]]></kwd>
<kwd lng="es"><![CDATA[eccema]]></kwd>
<kwd lng="es"><![CDATA[infección pulmonar]]></kwd>
<kwd lng="es"><![CDATA[abscesos fríos]]></kwd>
<kwd lng="es"><![CDATA[inmunodeficiencia congénita]]></kwd>
<kwd lng="en"><![CDATA[hyperimmunoglobulin E syndrome]]></kwd>
<kwd lng="en"><![CDATA[Job's syndrome]]></kwd>
<kwd lng="en"><![CDATA[eczema]]></kwd>
<kwd lng="en"><![CDATA[lung infection]]></kwd>
<kwd lng="en"><![CDATA[cold abscesses]]></kwd>
<kwd lng="en"><![CDATA[congenital immunodeficiency]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  	    <p align="justify"><font face="verdana" size="4">Caso cl&iacute;nico</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="4"><b>S&iacute;ndrome de hiperinmunoglobulinemia E. Reporte de dos casos</b></font></p>  	    <p align="center"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="3"><b>Hyperimmunoglobulin E syndrome: report of two cases</b></font></p>  	    <p align="center"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="center"><font face="verdana" size="2"><b>Miriam Puebla&#45;Miranda<sup>1</sup>, Eduwiges Mart&iacute;nez&#45;Luna<sup>2</sup>, Mar&iacute;a Elisa Vega&#45;Memije<sup>2</sup></b></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><sup><i>1</i></sup> <i>Departamento de Dermatolog&iacute;a Hospital General "Dr. Manuel Gea Gonz&aacute;lez", Secretar&iacute;a de Salud, M&eacute;xico, D. R, M&eacute;xico.</i></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><i><sup>2</sup> Servicio de Dermatopatolog&iacute;a, Hospital General "Dr. Manuel Gea Gonz&aacute;lez", Secretar&iacute;a de Salud, M&eacute;xico, D. R, M&eacute;xico.</i></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Autor de correspondencia:</b>    <br> 	<i>Mar&iacute;a Elisa Vega Memije</i> <i>    <br> </i> Correo electr&oacute;nico: <a href="mailto:dra_elisa_vega@yahoo.com.mx">dra_elisa_vega@yahoo.com.mx</a></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2">Fecha de recepci&oacute;n: 29&#45;04&#45;08    <br> 	Fecha de aprobaci&oacute;n: 29&#45;01&#45;09</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Resumen</b></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><b>Introducci&oacute;n.</b> El s&iacute;ndrome de hiperinmunoglobulinemia E es una inmunodeficiencia sist&eacute;mica poco frecuente, caracterizada por dermatitis eccematosa, abscesos fr&iacute;os recurrentes, infecciones pulmonares con formaci&oacute;n de neumatoceles, facies tosca, niveles elevados de inmunoglobulina E (IgE) en suero y eosinofilia.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Casos cl&iacute;nicos.</b> Caso 1. Femenino de 11 a&ntilde;os de edad con antecedentes de neumon&iacute;a recurrente, gastroenteritis de repetici&oacute;n, dermatitis eccematosa de predominio en pliegues, y abscesos fr&iacute;os; en estudios de laboratorio destac&oacute; el hallazgo de 16 070 eosin&oacute;filos e IgE de 4 864 Ul. Manejada con gammaglobulina se observ&oacute; buena respuesta cl&iacute;nica. Caso 2. Femenino de 12 a&ntilde;os de edad con historia de otitis recurrente y conjuntivitis supurativa, presentaba eccema cr&oacute;nico generalizado e impetiginizado. En estudios de laboratorio se report&oacute; IgE de 3 000 UI; fue manejada con dapsona, trimetropim/sulfametoxazol y metotrexate.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Conclusi&oacute;n.</b> Los 2 casos aqu&iacute; informados presentaron piel eccematosa, infecciones recurrentes e incremento de los niveles de IgE, compatibles con s&iacute;ndrome de hiperinmunoglobulinemia E en la forma autos&oacute;mica recesiva.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Palabras clave:</b> S&iacute;ndrome de hiperinmunoglobulinemia E, s&iacute;ndrome de Job, eccema, infecci&oacute;n pulmonar, abscesos fr&iacute;os, inmunodeficiencia cong&eacute;nita.</font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Abstract</b></font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Background.</b> Hyperimmunoglobulin E syndrome is a rare systemic immunodeficiency characterized by eczematous dermatitis, recurrent cold abscesses, lung infections with pneumatoceles, coarse facial appearance, high IgE levels and eosinophilia.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Case reports.</b> Case 1: We report the case of an 11&#45;year&#45;old female with a history of recurrent lung infections, recurrent gastroenteritis, eczematous dermatitis affecting the skin folds and cold abscesses. Laboratory studies showed elevated eosinophils (16 070) and IgE 4864 IU. The patient received treatment with g&#45;globulin, showing adequate clinic response to treatment. Case 2: We present the case of a 12&#45;year&#45;old female with a history of recurrent otitis and suppurative conjunctivitis, showing widespread and chronic infected eczema. Laboratory studies showed elevated IgE (3 000 IU). She was treated with dapsone, trimethoprim/sulfamethoxazole and methotrexate.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Conclusions.</b> We presented two patients with eczematous skin, recurrent infections and increased IgE levels, which are compatible with hyperimmunoglobulin E autosomal recessive syndrome.</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Key words:</b> hyperimmunoglobulin E syndrome, Job's syndrome, eczema, lung infection, cold abscesses, congenital immunodeficiency.</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Introducci&oacute;n</b></font></p>  	    <p align="justify"><font face="verdana" size="2">El s&iacute;ndrome de hiperinmunoglobulinemia E fue descrito por primera vez en 1966 por Davis y col.<sup>1</sup> al reportar dos ni&ntilde;as con pelo rojo, dermatitis cr&oacute;nica severa, abscesos fr&iacute;os y neumon&iacute;a recurrente, denominando a esta enfermedad s&iacute;ndrome de Job en alusi&oacute;n al personaje b&iacute;blico Job, cuya fe se prob&oacute; al soportar &uacute;lceras y f&iacute;stulas que drenaron de por vida. Posteriormente, en 1972, Buckley y col.<sup>2</sup> describieron este s&iacute;ndrome en dos ni&ntilde;os con dermatitis severa, abscesos recurrentes a nivel cut&aacute;neo, pulmonar y articular, retardo en el crecimiento, facies tosca e hipersensibilidad inmediata exagerada asociada con niveles elevados de inmunoglobulina E (IgE) en suero y eosinofilia, por lo que tambi&eacute;n se le conoce como s&iacute;ndrome de Buckley; sin embargo, recientemente se trata de omitir los ep&oacute;nimos y se recomienda llamarlo s&iacute;ndrome de hiperinmunoglobulinemia E o s&iacute;ndrome hiper IgE. Esta alteraci&oacute;n es producida por un defecto gen&eacute;tico que ocasiona la producci&oacute;n de niveles s&eacute;ricos elevados de anticuerpos IgE; el eccema e infecciones recurrentes son caracter&iacute;sticos. Es una enfermedad extremadamente rara, a la fecha solo existen aproximadamente 250 casos reportados en la literatura.<sup>3</sup> En la mayor&iacute;a de los casos se hereda de manera autos&oacute;mica dominante y predominan las manifestaciones dentales y alteraciones &oacute;seas;<sup>4</sup> la forma de herencia autos&oacute;mica recesiva se asocia a infecciones f&uacute;ngicas o virales graves. El uso de gammaglobulina intravenosa a altas dosis ha sido eficaz en el tratamiento de esta enfermedad. En este art&iacute;culo se informa de dos casos de s&iacute;ndrome de hiperinmunoglobulinemia E en su forma autos&oacute;mica recesiva.<sup>56</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Presentaci&oacute;n de los casos cl&iacute;nicos</b></font></p>  	    <p align="justify"><font face="verdana" size="2"><i>Caso 1.</i> Paciente del sexo femenino de 11 a&ntilde;os de edad, originaria y residente de Zimapam, Hidalgo, que se encontraba hospitalizada en una instituci&oacute;n de tercer nivel con diagn&oacute;stico de neumon&iacute;a (<a href="#f1">Fig. 1</a>). Se solicit&oacute; interconsulta al Servicio de Dermatolog&iacute;a por presentar dermatosis diseminada bilateral y sim&eacute;trica, que afectaba las comisuras de la boca, cuello, pliegues axilares, antecubitales, inguinales y vulva; la dermatosis estaba constituida por grandes placas mal definidas, conformadas por eritema, costras melic&eacute;ricas y hem&aacute;ticas, exulceraci&oacute;n y piel de aspecto eccematoso; en otras &aacute;reas predominaba la liquenificaci&oacute;n, las costras hem&aacute;ticas y la hiperpigmentaci&oacute;n residual. A nivel axilar e inguinal hab&iacute;a aumento de volumen y f&iacute;stulas con salida de material purulento sin aumento de temperatura o eritema local (abscesos fr&iacute;os) (<a href="/img/revistas/bmim/v66n6/a9f2.jpg" target="_blank">Fig. 2</a>). Presentaba desnutrici&oacute;n con peso de 23 kg y talla de 125 cm; a nivel de cara con puente nasal ancho y punta redonda (<a href="#f3">Fig. 3</a>).</font></p>  	    <p align="center"><font face="verdana" size="2"><a name="f1"></a></font></p>  	    <p align="center"><font face="verdana" size="2"><img src="/img/revistas/bmim/v66n6/a9f1.jpg"></font></p>  	    <p align="center"><font face="verdana" size="2"><a name="f3"></a></font></p>  	    <p align="center"><font face="verdana" size="2"><img src="/img/revistas/bmim/v66n6/a9f3.jpg"></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">Al interrogatorio indirecto se refiri&oacute; exantema al nacimiento, el cual mejor&oacute; con tratamiento t&oacute;pico no especificado y desde los cinco a&ntilde;os de edad present&oacute; lesiones similares a las ya descritas, cursando con remisiones parciales y exacerbaciones.</font></p>  	    <p align="justify"><font face="verdana" size="2">En los resultados de laboratorio destac&oacute; la eosinofilia de 82% (0&#45;7% normal) con una cuenta absoluta de 16 070 (0&#45;0.8/<i>&#956;</i>L) eosin&oacute;filos, y la inmunoglobulina E de 4 864 UI/mL (0&#45;100 UI/mL); la interleucina (I L)&#45;12 y la IL&#45;2 estaban disminuidas y el interfer&oacute;n gamma y la IL&#45;4 se reportaron levemente aumentados, con valores de c&eacute;lulas NK normales. El coproparasitosc&oacute;pico revel&oacute; quistes de <i>Giardia lamblia,</i> para lo cual se dio tratamiento con metronidazol.</font></p>  	    <p align="justify"><font face="verdana" size="2">Con estos datos se consider&oacute; inidalmente el diagn&oacute;stico de eccema at&oacute;pico; sin embargo, llamaba la atenci&oacute;n el antecedente de dos hospitalizaciones a los cuatro y siete a&ntilde;os de edad por neumon&iacute;a, manejada con claritromicina, ketoconazol y cefatoxirma. Adem&aacute;s de tener el antecedente de gastroenteritis de repetici&oacute;n desde los cinco a&ntilde;os de edad con evacuaciones f&eacute;tidas y con moco. A los 10 a&ntilde;os de edad present&oacute; abscesos fr&iacute;os en piel y en el a&ntilde;o 2005 se le hab&iacute;a realizado cultivo de un ganglio inguinal que report&oacute; adiaspiromicosis PAS positiva por <i>Chysosporium parvum.</i> En el a&ntilde;o 2006 se le realiz&oacute; biopsia pulmonar por una imagen radiopaca en radiograf&iacute;a de t&oacute;rax, reportando lesi&oacute;n granulomatosa. La intradermorreacci&oacute;n con PPD fue negativa.</font></p>  	    <p align="justify"><font face="verdana" size="2">Al interrogatorio dirigido se neg&oacute; consanguinidad de los padres, siendo producto de la gesta VI11, con dos hermanos finados, uno al a&ntilde;o de edad por padecimiento dermatol&oacute;gico no especificado y el otro por cuadro s&eacute;ptico; el resto de los hermanos los refirieron como sanos.</font></p>  	    <p align="justify"><font face="verdana" size="2">Con lo anterior se realiz&oacute; una biopsia cut&aacute;nea que sugiri&oacute; los diagn&oacute;sticos de eccema secundario a s&iacute;ndrome de hiperinmunoglobulinemia E contra enfermedad granulomatosa cr&oacute;nica.</font></p>  	    <p align="justify"><font face="verdana" size="2">La histopatolog&iacute;a de piel mostr&oacute; espongiosis, vacuolizaci&oacute;n focal de la capa basal, exodtosis de eosin&oacute;filos, infiltrado inflamatorio superficial y profundo, perivascular e intersticial, constituido por eosin&oacute;filos, algunos linfocitos e histiocitos (<a href="#f4">Fig. 4</a>).</font></p>  	    <p align="center"><font face="verdana" size="2"><a name="f4"></a></font></p>  	    <p align="center"><font face="verdana" size="2"><img src="/img/revistas/bmim/v66n6/a9f4.jpg"></font></p>  	    <p align="justify"><font face="verdana" size="2">Se integr&oacute; el diagn&oacute;stico de s&iacute;ndrome de hiperinmunoglobulinemia E. La paciente fue tratada durante su hospitalizaci&oacute;n con ceftriaxona y amikacina por la neumon&iacute;a, y a nivel t&oacute;pico para el eccema, con mupirocina mezclado con aceponato de metilprednisolona dos veces por d&iacute;a y con fomentos secantes, observando buena respuesta al tratamiento. Se egres&oacute; con profilaxis a base de trimetoprim/sulfametoxazol e itraconazol y se inici&oacute; gammaglobulina a dosis de 400 mg/kg de peso.</font></p>  	    <p align="justify"><font face="verdana" size="2">Posteriormente, a los tres meses de su egreso, la paciente fue hospitalizada por bronquiectasias infectadas; el cultivo de expectoraci&oacute;n report&oacute; <i>Entamoeba coli y Branhamella catarrhalis.</i> Present&oacute; eosinofilia de 90% con 17 480 eosin&oacute;filos totales; recibi&oacute; tratamiento con ceftriaxona, amikacina, gammaglobulina a 500 mg/kg de peso, y a su egreso se decidi&oacute; aumentar la gammaglobulina a 1 g/kg de peso, con buena respuesta cl&iacute;nica.</font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2"><i>Caso 2.</i> Paciente femenino de 12 a&ntilde;os de edad originaria y residente de Oaxaca, Oaxaca, hospitalizada en pediatr&iacute;a con los diagn&oacute;sticos de impetigo generalizado, conjuntivitis y otitis media supurativa.</font></p>  	    <p align="justify"><font face="verdana" size="2">Se interconsult&oacute; al servicio de dermatolog&iacute;a por presentar dermatosis generalizada, bilateral y sim&eacute;trica, afectando todos los segmentos corporales, constituida en piel cabelluda por placas pseudoalop&eacute;cicas, escama, costras serosangu&iacute;neas y melic&eacute;ricas, en el resto se observaba con p&aacute;pulas, p&uacute;stulas y placas eccematosas impetiginizadas, as&iacute; como maceraci&oacute;n de pliegues (<a href="/img/revistas/bmim/v66n6/a9f5.jpg" target="_blank">Fig. 5</a>). A la exploraci&oacute;n f&iacute;sica presentaba adenopat&iacute;as submaxilares, axilares e inguinales, con cinco meses de evoluci&oacute;n, iniciando la dermatosis en pliegues, con diseminaci&oacute;n progresiva; fue manejada con fomentos de sulfato de cobre 1:1000, didoxadlina, cloramfenicol oft&aacute;lmico y loratadina/betametasona a 5 mg/0.25mg cada ocho horas. En los estudios de laboratorio resaltaba: leucocitosis, eosinofilia y bandemia; con cultivo de exudado positivo para <i>E. coli.</i> Se decidi&oacute; su egreso por mejor&iacute;a, con impresi&oacute;n diagn&oacute;stica de dermatitis at&oacute;pica impetiginizada.</font></p>  	    <p align="justify"><font face="verdana" size="2">Dos meses despu&eacute;s acudi&oacute; nuevamente con fiebre no cuantificada, hiperemia conjuntival, secreci&oacute;n ocular verdosa, otitis externa y eccema generalizado, por lo que nuevamente se hospitaliz&oacute;. Fue manejada con fomentos de sulfato de cobre, vioformoydidoxacilina por la sospecha diagn&oacute;stica de dermatitis at&oacute;pica impetiginizada (cultivo positivo para <i>Staphyloccocus aureus y E. coli);</i> se agreg&oacute; hidroxicina 1 mg/kg/d&iacute;a, prednisona 0.7 mg/kg/d&iacute;a e isoniacida a 300 mg/d&iacute;a como profilaxis para tuberculosis por el antecedente de Combe +. Se realiz&oacute; la toma de biopsia para estudio histopatol&oacute;gico, en donde destac&oacute; la espongiosis de la epidermis e infiltrado inflamatorio por linfocitos y eosin&oacute;filos.</font></p>  	    <p align="justify"><font face="verdana" size="2">Ante los antecedentes de otitis externa recurrente (<a href="#f6">Fig. 6</a>), motivo por el cual la paciente acud&iacute;a regularmente al Servicio de Otorrinolaringolog&iacute;a, de los episodios de eccema generalizado impetiginizado, as&iacute; como de conjuntivitis, se estableci&oacute; el diagn&oacute;stico probable de s&iacute;ndrome de hiperinmunoglobulinemia E, y se determinaron niveles de IgE s&eacute;ricos con un valor de 3 000 UI (0&#45;100 UI/mL valor de referencia), con lo que se confirm&oacute; el diagn&oacute;stico. Fue egresada con manejo de dapsona 100 mg/ d&iacute;a, trimetropim/sulfametoxazol 160/800 mg/d&iacute;a y metotrexate; la paciente no acudi&oacute; posteriormente para continuar seguimiento. No se registr&oacute; la existencia de consanguinidad de los padres u otros antecedentes familiares de importancia.</font></p>  	    <p align="center"><font face="verdana" size="2"><a name="f6"></a></font></p>  	    <p align="center"><font face="verdana" size="2"><img src="/img/revistas/bmim/v66n6/a9f6.jpg"></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Discusi&oacute;n</b></font></p>  	    <p align="justify"><font face="verdana" size="2">El s&iacute;ndrome de hiperinmunoglobulinemia E es una inmunodeficiencia sist&eacute;mica rara, caracterizada por la tr&iacute;ada cl&aacute;sica de niveles altos de inmunoglobulina E, eccema e infecciones recurrentes. Presenta una incidencia de 1 en 500 000 nacidos vivos, sin predominio de g&eacute;nero; hasta la fecha existen aproximadamente 250 casos reportados en la literatura.<sup>3</sup> La forma de transmisi&oacute;n m&aacute;s frecuente es la autos&oacute;mica dominante con penetrando variable. Por estudios citogen&eacute;ticos se ha sugerido que la alteraci&oacute;n se encuentra a nivel del brazo largo del cromosoma 4, predominando las manifestaciones dentales y alteraciones &oacute;seas.<sup>4</sup> En cuanto a la transmisi&oacute;n autos&oacute;mica recesiva, se ha puntualizado la mutaci&oacute;n del gen Tyk2, caracteriz&aacute;ndose por presentar infecciones f&uacute;ngicas o virales graves y manifestaciones del sistema nervioso centraren donde puede ocurrir infarto isqu&eacute;mico, hemorragia subaracnoidea y hemiplej&iacute;a.<sup>56</sup> En estudios recientes se han precisado como determinantes en la etiolog&iacute;a de este s&iacute;ndrome, en su forma dominante o espor&aacute;dica, mutaciones en el gen STAT3; este gen interviene directamente en la respuesta de los monocitos a la IL&#45;6, en consecuencia se produce disminuci&oacute;n de la prote&iacute;na 1 quimioatrayente de monocitos, adem&aacute;s juega un papel en el desarrollo y diferenciaci&oacute;n de c&eacute;lulas B y Th 17, y en la se&ntilde;alizaci&oacute;n de otras atocinas como la IL&#45;10e IL&#45;17.<sup>7,11</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">En estos pacientes existe disminuci&oacute;n en la quimiotaxis de neutr&oacute;filos. Se considera que en su patog&eacute;nesis interviene la disminuci&oacute;n de receptores C3b en neutr&oacute;filos, as&iacute; como la disminuci&oacute;n de la mol&eacute;cula de adhesi&oacute;n L&#45;selectina en los granulocitosylinfocitos.<sup>12</sup></font></p>  	    ]]></body>
<body><![CDATA[<p align="justify"><font face="verdana" size="2">La elevaci&oacute;n de IgE en suero se asocia espec&iacute;ficamente con la formaci&oacute;n de anticuerpos contra S. <i>aureus;</i> es caracter&iacute;stico encontrar niveles de IgE de m&aacute;s de 20 veces su valor normal (&gt; 2000 UI/mL), con una cuenta elevada de eosin&oacute;filos en sangre. La eosinofilia se asocia con un incremento en la producci&oacute;n de GM&#45;CSF y disminuci&oacute;n deTGF&#45;<i>&#946;</i>. La IL&#45;4 en general es normal. Adem&aacute;s hay disminuci&oacute;n de la producci&oacute;n de interfer&oacute;n y y factor de necrosis tumoral, con una pobre respuesta a la estimulaci&oacute;n por IL&#45;12, disminuci&oacute;n en la poblaci&oacute;n de linfocitos B de memoria y de la respuesta de hipersensibilidad tard&iacute;a. Existe un aumento en la producci&oacute;n de intermediarios reactivos de ox&iacute;geno por los neutr&oacute;filos, lo que explica el da&ntilde;o tisular.<sup>13,14</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">En los estudios realizados se han descrito las alteraciones asociadas al s&iacute;ndrome, con la tr&iacute;ada cl&aacute;sica de abscesos de la piel y neumon&iacute;as recurrentes, adem&aacute;s de niveles elevados de IgE; el eccema severo es un hecho universal.<sup>15,16</sup> As&iacute; mismo, se describe una facies tosca caracter&iacute;stica, sin que la apariencia sea completamente dism&oacute;rfica; las caracter&iacute;sticas eraneofac&iacute;ales m&aacute;s relevantes son las cejas prominentes, con la apariencia de ojos hundidos, puente y punta nasal anchos, labio inferior grueso, asimetr&iacute;a facial, frente prominente, hipertelorismo, prognatismo y piel facial &aacute;spera con poros dilatados.<sup>17</sup> S&oacute;lo la paciente del primer caso presentaba estas caracter&iacute;sticas.</font></p>  	    <p align="justify"><font face="verdana" size="2">En un intento por establecer datos tempranos de la enfermedad se ha observado que 74% de los pacientes presentan prurito antes de los dos a&ntilde;os de vida, 72% tiene historia de eccema flexural, y 81 % antecedente de exantema del reci&eacute;n nacido durante el primer mes de vida. Aunque a&uacute;n no est&aacute;n establecidos los datos tempranos para el diagn&oacute;stico debido a que inicialmente no se presentan las principales caracter&iacute;sticas, como la dermatitis eccematosa, algunos autores proponen tomar en cuenta, dentro de los diagn&oacute;sticos diferenciales de exantemas m&aacute;culov&eacute;siculo&#45;pustulares en neonatos, al s&iacute;ndrome de hiperinmunoglobulinemia E.<sup>18,20</sup> La paciente del caso uno tiene el antecedente de exantema al nacimiento y, al momento de la interconsulta de eccema y liquenificaci&oacute;n, lesiones frecuentes en pacientes con dermatitis at&oacute;pica; en la paciente del caso dos, adem&aacute;s del eccema con impetiginizaci&oacute;n secundaria, sobresale el antecedente de infecciones &oacute;ticas recurrentes y conjuntivitis. Los pacientes con s&iacute;ndrome de hiperinmunoglobulinemia E autos&oacute;mica recesiva presentan con m&aacute;s frecuencia infecciones virales por molusco contagioso y herpes simple; adem&aacute;s, tienen una alta frecuencia de alteraciones del sistema nervioso central.<sup>5</sup> Estos datos no se encontraron en los casos que aqu&iacute; se informan.</font></p>  	    <p align="justify"><font face="verdana" size="2">Entre las alteraciones dentales reportadas est&aacute;n la retenci&oacute;n primaria de dientes, o no erupci&oacute;n de dientes permanentes, la presencia de dientes primarios y dientes permanentes al mismo tiempo y elevaci&oacute;n del paladar; la paciente del primer caso tuvo historia de retardo en la dentici&oacute;n; sin embargo, a la exploraci&oacute;n f&iacute;sica no se encontraron alteraciones dentales.<sup>21,22</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">Con respecto al tratamiento, no hay uno curativo a&uacute;n, por lo que las decisiones terap&eacute;uticas se basan en las manifestaciones cl&iacute;nicas. La terap&eacute;utica m&aacute;s efectiva es el uso de antibi&oacute;ticos sist&eacute;micos profil&aacute;cticos, con cobertura dirigida contra S. <i>aureus.</i> Hay reportes de casos de mejor&iacute;a cl&iacute;nica e inmunol&oacute;gica de la dermatitis eccematosa, disminuci&oacute;n en la frecuencia de abscesos fr&iacute;os, de IgE y de la eosinofilia con el uso continuo detrimetoprim/sulfametoxazol (40 mg/kg/d&iacute;a/8 mg/kg/d&iacute;a); sin embargo, los efectos evaluados <i>in vitro</i> de este antibi&oacute;tico a nivel de la quimiotaxis de neutr&oacute;filos y producci&oacute;n de hidr&oacute;geno, no fueron reproducibles y se desconoce hasta el momento el mecanismo de acci&oacute;n.<sup>23,24</sup> Se ha reportado el uso de inmunoglobulina intravenosa en algunos casos, con resultados poco satisfactorios;<sup>25</sup>sin embargo, otro estudio realizado por Kirmata<sup>26</sup> menciona una adecuada respuesta al manejo con gammaglobulina intravenosa a altas dosis (400 mg/kg/d&iacute;a) durante 5 d&iacute;as, se observa reducci&oacute;n en la severidad del eccema, adem&aacute;s de presentar disminuci&oacute;n de la producci&oacute;n de IgE <i>in vivo e in vitro.<sup>27</sup> <sup>,29</sup></i> Otro f&aacute;rmaco utilizado es el interfer&oacute;n gamma, que incrementa el &iacute;ndice quimiot&aacute;ctico basal.<sup>27</sup> Existen reportes de casos con &eacute;xito terap&eacute;utico secundario al uso de isotretinoina, sin que hasta el momento se conozca el posible mecanismo de acci&oacute;n.<sup>28</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">Respecto a la predisposici&oacute;n a malignidad, hasta la fecha no se ha probado que &eacute;sta aumente; s&oacute;lo se han reportado casos que mencionan alguna asociaci&oacute;n con neoplasias hematol&oacute;gicas.<sup>30,34</sup></font></p>  	    <p align="justify"><font face="verdana" size="2">&nbsp;</font></p>  	    <p align="justify"><font face="verdana" size="2"><b>Referencias</b></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">1. Davis SD, Schaller J, Wedgwood RJ. Job's syndrome: recurrent, "cold", staphylococcal abscesses. Lancet 1966,1:1013&#45;1015.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511351&pid=S1665-1146200900060000900001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">2. Buckley RH, Wray BB, Elmaker EZ. Extreme hyperimmunoglobulinemia E and undue susceptibility to infection. Pediatrics 1972,49:69&#45;70.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511353&pid=S1665-1146200900060000900002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">3. De Witt CA, Bishop AB, Buescher L, Stone S. Hyperimmunoglobulin E syndrome: Two cases and review of the literature. J Am Acad Dermatol 2006,54:855&#45;865.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511355&pid=S1665-1146200900060000900003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">4. Grimbacher B, Holland SM, Gallin Jl, Greenberg F, Hill SC, Malech HL, et al. Hyper&#45;IgE syndrome with recurrent infections. An autosomal dominant multisystem disorder. N Engl J Med 1999,340:692&#45;702.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511357&pid=S1665-1146200900060000900004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">5. Renner ED, Puck J, Holland S, Schmitt M, Weiss M, Frosch M, et al. Autosomal recessive hyperimmunoglobulin E syndrome: A distinct disease entity. J Pediatr 2004; 144:93&#45;99.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511359&pid=S1665-1146200900060000900005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">6. Verma S, Wollina U. Job's syndrome&#45;a case report. JEADV 2003; 17:711&#45;714.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511361&pid=S1665-1146200900060000900006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">7. MinegishiY, Karasuyama H. Genetic origins of hyper&#45;IgE syndrome. Curr Allergy Asthma Rep 2008,8:386&#45;391.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511363&pid=S1665-1146200900060000900007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">8. Holland S, DeLeo F, Elloumi H, Hsu A, Uzel G, Brodsky N, et al. STAT3 Mutations in the hyper&#45;IgE syndrome. N Engl J Med 2007,357:1608&#45;1619.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511365&pid=S1665-1146200900060000900008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">9. Paulson M, Freeman A, Holland S. Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3. Curr Opin Allergy Clin Immunol 2008,8:527&#45;533.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511367&pid=S1665-1146200900060000900009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">10. Jiao H, Toth B, Erdos M, Fransson I, Rakoczi E, Balogh I, et al. Novel and recurrent STAT3 mutations in hyper&#45;IgE syndrome patients from different ethnic groups. Mol Immunol 2008,46:202&#45;206.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511369&pid=S1665-1146200900060000900010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">11. MilnerJD, BrenchleyJM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impared T(H)17 cell differentiation in subjects with autosoman dominant hyper&#45;IgE syndrome. Nature 2008,452:773&#45;776.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511371&pid=S1665-1146200900060000900011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">12. Vargas L, Rodr&iacute;guez M, Forero C, Montoya F, Montoya C, Sorensen R, et al. Increase in granulocyte&#45;macrophage&#45;colony&#45;stimulating factor secretion and the respiratory burst with decreased L&#45;selectin expression in hyper&#45;IgE syndrome patients. Ann Allergy Asthma Immunol 1999,83:245&#45;251.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511373&pid=S1665-1146200900060000900012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">13. Stiehm E. Cytokine dysregulation in the hyperimmunoglobulinemia E syndrome. J Pediatr 2000,136:141&#45;143.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511375&pid=S1665-1146200900060000900013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">14. Speckmann C, Enders A, Woellner C, Thiel D, Rensing&#45;Ehl A, Schlesier M, et al. Reduced memory B cell in patient with hyper IgE syndrome. Clin Immunol 2008,129:448&#45;454.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511377&pid=S1665-1146200900060000900014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">15. Freeman A, Holland S. The hyper&#45;lgE syndromes. Immunol Allergy Clin North Am 2008,28:277&#45;291.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511379&pid=S1665-1146200900060000900015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">16. Chamlin S, McCalmont T, Cunningham B, Esterly N, Lai C, Mallory S, et al. Cutaneous manifestations of hyper&#45;IgE syndrome in infants and children. J Pediatr 2002,141:572&#45;575.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511381&pid=S1665-1146200900060000900016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">17. Borges W, Hensley T, Carey J, Petrak B, Hill H. The face of Job. J Pediatr 1998,133:303&#45;305.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511383&pid=S1665-1146200900060000900017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">18. Eberting CL, Davis J, Puck J, Holland S, Turner M. Dermatitis and the newborn rash of hyper&#45;IgE syndrome. Arch Dermatol 2004; 140:11 19&#45;125.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511385&pid=S1665-1146200900060000900018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">19. Kamei R, Honig R Neonatal Job's syndrome featuring a vesicular eruption. Pediatr Dermatol 1988,5:75&#45;82.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511387&pid=S1665-1146200900060000900019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">20. Erlewin&#45;Lajeunesse M. Hyperimmunoglobulin&#45;E syndrome with recurrent infection: a review of current opinion and treatment. Pediatr Allergy Immunol 2000,11:133&#45;141.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511389&pid=S1665-1146200900060000900020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">21. Freeman AF, Domingo DL, Holland SM. Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations. Oral Dis 2009; 15:2&#45;7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511391&pid=S1665-1146200900060000900021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">22. Aldous J, Olson G, Parkin M. Dental observations of hyper IgE disorder. J Clin Pediatr Dent 2007,32:69&#45;72.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511393&pid=S1665-1146200900060000900022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">23. Hattori K, Hasui M, Masuda K, Masuda M, Ogino H, Kobayashi Y. Successful trimethoprimsulfamethoxazole therapy in a patient with hyperimmunoglobulin E syndrome. Acta Paediatr 1993,82:324&#45;326.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511395&pid=S1665-1146200900060000900023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">24. Tanaka H, Ito R, Onodera N, Waga S. Efficacy of long&#45;term sulfamethoxazoletrimethoprim therapy in a boy with hyperimmunoglobulin E syndrome. Tohoku J Exp Med 1998; 186:61&#45;66.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511397&pid=S1665-1146200900060000900024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">25. Wakim M, Alazard M, Yajima A, Speight D, Saxon A, Stiehm R. High dose intravenous immunoglobin in atopic dermatitis and hyper&#45;IgE syndrome. Ann Allergy Asthma Immunol 1998,81:153&#45;158.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511399&pid=S1665-1146200900060000900025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">26. Kimata H. Highdose intravenous &#947;&#45;globulin treatment for hyperimmunoglobulin E syndrome. J Allergy Clin Immunol 1995,95:771&#45;774.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511401&pid=S1665-1146200900060000900026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">27. Jeppson J, Jaffe H, Hill H. Use of recombinant human inter&#45;feron gamma to enhance neutrophil chemotactic responses in Job's syndrome of hyperimmunoglobulinemia E and recurrent infections. J Pediatr 1991,118:383&#45;387.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511403&pid=S1665-1146200900060000900027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">28. Shuttleworth D, Holt P, Mathews N. Hyperimmunoglobulin E syndrome: Treatment with isotretinoin. Br J Dermatol 1988; 119:93&#45;99.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511405&pid=S1665-1146200900060000900028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">29. Orozco C, Velazquez L, M&eacute;ndez N, Augusto B, Solazar T Hyper IgE syndrome. Opportune diagnosis and management. Rev Alerg Mex 2008;55:38&#45;45.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511407&pid=S1665-1146200900060000900029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">30. Lin SJ, Huang JL, Hsieh KH. Hodgkin's disease in a child with hyperimmunoglobulin E syndrome. Pediatr Hematol Oncol 1998; 15:451&#45;454.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511409&pid=S1665-1146200900060000900030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">31. Bale J, Wilson J, Hill H. Fatal histiocytic lymphoma of the brain associated with hyperimmunoglobulin&#45;E and recurrent infections. Cancer 1977,39:2386&#45;2390.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511411&pid=S1665-1146200900060000900031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    ]]></body>
<body><![CDATA[<!-- ref --><p align="justify"><font face="verdana" size="2">32. Gorin L, Jeha S, Sullivan M. Burkitt's lymphoma developing in a 7 year&#45;old boy with hyper&#45;IgE syndrome. J Allergy Clin Immunol 1989;83:5&#45;10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511413&pid=S1665-1146200900060000900032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">33. Onal I, Kurt M, Altundag K, Aksoy S, Dincer M, Gullu I. Peripheral T&#45;cell lymphoma and Job's syndrome: a rare association. Med Oncol 2006;23:141&#45;144.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511415&pid=S1665-1146200900060000900033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>  	    <!-- ref --><p align="justify"><font face="verdana" size="2">34. Amlot P, Green L Atopy and immunoglobulin E concentrations in Hodgkin's disease and other lymphomas. BMJ 1978; 1:327&#45;329.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=1511417&pid=S1665-1146200900060000900034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Schaller]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wedgwood]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Job's syndrome: recurrent, "cold", staphylococcal abscesses]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1966</year>
<volume>1</volume>
<page-range>1013-1015</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buckley]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Wray]]></surname>
<given-names><![CDATA[BB]]></given-names>
</name>
<name>
<surname><![CDATA[Elmaker]]></surname>
<given-names><![CDATA[EZ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Extreme hyperimmunoglobulinemia E and undue susceptibility to infection]]></article-title>
<source><![CDATA[Pediatrics]]></source>
<year>1972</year>
<volume>49</volume>
<page-range>69-70</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Witt]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bishop]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Buescher]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyperimmunoglobulin E syndrome: Two cases and review of the literature]]></article-title>
<source><![CDATA[J Am Acad Dermatol]]></source>
<year>2006</year>
<volume>54</volume>
<page-range>855-865</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grimbacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Gallin]]></surname>
<given-names><![CDATA[Jl]]></given-names>
</name>
<name>
<surname><![CDATA[Greenberg]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Malech]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyper-IgE syndrome with recurrent infections. An autosomal dominant multisystem disorder]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<page-range>692-702</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Renner]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Puck]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Frosch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Autosomal recessive hyperimmunoglobulin E syndrome: A distinct disease entity]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2004</year>
<volume>144</volume>
<page-range>93-99</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wollina]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Job's syndrome-a case report]]></article-title>
<source><![CDATA[JEADV]]></source>
<year>2003</year>
<volume>17</volume>
<page-range>711-714</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minegishi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Karasuyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic origins of hyper-IgE syndrome]]></article-title>
<source><![CDATA[Curr Allergy Asthma Rep]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>386-391</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[DeLeo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Elloumi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Uzel]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Brodsky]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[STAT3 Mutations in the hyper-IgE syndrome]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2007</year>
<volume>357</volume>
<page-range>1608-1619</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paulson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyper IgE syndrome: an update on clinical aspects and the role of signal transducer and activator of transcription 3]]></article-title>
<source><![CDATA[Curr Opin Allergy Clin Immunol]]></source>
<year>2008</year>
<volume>8</volume>
<page-range>527-533</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiao]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Toth]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Erdos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fransson]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Rakoczi]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Balogh]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Novel and recurrent STAT3 mutations in hyper-IgE syndrome patients from different ethnic groups]]></article-title>
<source><![CDATA[Mol Immunol]]></source>
<year>2008</year>
<volume>46</volume>
<page-range>202-206</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Milner]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Brenchley]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Laurence]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Elias]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Impared T(H)17 cell differentiation in subjects with autosoman dominant hyper-IgE syndrome]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2008</year>
<volume>452</volume>
<page-range>773-776</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Forero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Montoya]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sorensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increase in granulocyte-macrophage-colony-stimulating factor secretion and the respiratory burst with decreased L-selectin expression in hyper-IgE syndrome patients]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>1999</year>
<volume>83</volume>
<page-range>245-251</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stiehm]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytokine dysregulation in the hyperimmunoglobulinemia E syndrome]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2000</year>
<volume>136</volume>
<page-range>141-143</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Speckmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Enders]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Woellner]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thiel]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rensing-Ehl]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schlesier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Reduced memory B cell in patient with hyper IgE syndrome]]></article-title>
<source><![CDATA[Clin Immunol]]></source>
<year>2008</year>
<volume>129</volume>
<page-range>448-454</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The hyper-lgE syndromes]]></article-title>
<source><![CDATA[Immunol Allergy Clin North A]]></source>
<year>2008</year>
<volume>28</volume>
<page-range>277-291</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chamlin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[McCalmont]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Cunningham]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Esterly]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lai]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mallory]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cutaneous manifestations of hyper-IgE syndrome in infants and children]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>2002</year>
<volume>141</volume>
<page-range>572-575</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borges]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Hensley]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Petrak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The face of Job]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>1998</year>
<volume>133</volume>
<page-range>303-305</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eberting]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Puck]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Turner]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dermatitis and the newborn rash of hyper-IgE syndrome]]></article-title>
<source><![CDATA[Arch Dermatol]]></source>
<year>2004</year>
<volume>140</volume>
<page-range>19-125</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamei]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Honig]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neonatal Job's syndrome featuring a vesicular eruption]]></article-title>
<source><![CDATA[Pediatr Dermatol]]></source>
<year>1988</year>
<volume>5</volume>
<page-range>75-82</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Erlewin-Lajeunesse]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyperimmunoglobulin-E syndrome with recurrent infection: a review of current opinion and treatment]]></article-title>
<source><![CDATA[Pediatr Allergy Immunol]]></source>
<year>2000</year>
<volume>11</volume>
<page-range>133-141</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Domingo]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Holland]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyper IgE (Job's) syndrome: a primary immune deficiency with oral manifestations]]></article-title>
<source><![CDATA[Oral Dis]]></source>
<year>2009</year>
<volume>15</volume>
<page-range>2-7</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aldous]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Parkin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dental observations of hyper IgE disorder]]></article-title>
<source><![CDATA[]]></source>
<year>2007</year>
<volume>32</volume>
<page-range>69-72</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hattori]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hasui]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Masuda]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Masud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ogino]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kobayashi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Successful trimethoprimsulfamethoxazole therapy in a patient with hyperimmunoglobulin E syndrome]]></article-title>
<source><![CDATA[Acta Paediatr]]></source>
<year>1993</year>
<volume>82</volume>
<page-range>324-326</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Onodera]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Waga]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Efficacy of long-term sulfamethoxazoletrimethoprim therapy in a boy with hyperimmunoglobulin E syndrome]]></article-title>
<source><![CDATA[Tohoku J Exp Med]]></source>
<year>1998</year>
<volume>186</volume>
<page-range>61-66</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wakim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alazard]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yajima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Speight]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Saxon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Stiehm]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[High dose intravenous immunoglobin in atopic dermatitis and hyper-IgE syndrome]]></article-title>
<source><![CDATA[Ann Allergy Asthma Immunol]]></source>
<year>1998</year>
<volume>81</volume>
<page-range>153-158</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kimata]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Highdose intravenous &#947;-globulin treatment for hyperimmunoglobulin E syndrome]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>1995</year>
<volume>95</volume>
<page-range>771-774</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jeppson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Jaffe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of recombinant human inter-feron gamma to enhance neutrophil chemotactic responses in Job's syndrome of hyperimmunoglobulinemia E and recurrent infections]]></article-title>
<source><![CDATA[J Pediatr]]></source>
<year>1991</year>
<volume>118</volume>
<page-range>383-387</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shuttleworth]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Holt]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mathews]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyperimmunoglobulin E syndrome: Treatment with isotretinoin]]></article-title>
<source><![CDATA[Br J Dermatol]]></source>
<year>1988</year>
<volume>119</volume>
<page-range>93-99</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orozco]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Velazquez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Méndez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Augusto]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Solazar]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hyper IgE syndrome. Opportune diagnosis and management]]></article-title>
<source><![CDATA[Rev Alerg Mex]]></source>
<year>2008</year>
<volume>55</volume>
<page-range>38-45</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hodgkin's disease in a child with hyperimmunoglobulin E syndrome]]></article-title>
<source><![CDATA[Pediatr Hematol Oncol]]></source>
<year>1998</year>
<volume>15</volume>
<page-range>451-454</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bale]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hill]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fatal histiocytic lymphoma of the brain associated with hyperimmunoglobulin-E and recurrent infections]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1977</year>
<volume>39</volume>
<page-range>2386-2390</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jeha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Burkitt's lymphoma developing in a 7 year-old boy with hyper-IgE syndrome]]></article-title>
<source><![CDATA[J Allergy Clin Immunol]]></source>
<year>1989</year>
<volume>83</volume>
<page-range>5-10</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Onal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kurt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Altundag]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Aksoy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dincer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gullu]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Peripheral T-cell lymphoma and Job's syndrome: a rare association]]></article-title>
<source><![CDATA[Med Oncol]]></source>
<year>2006</year>
<volume>23</volume>
<page-range>141-144</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amlot]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Atopy and immunoglobulin E concentrations in Hodgkin's disease and other lymphomas]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1978</year>
<volume>1</volume>
<page-range>327-329</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
